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In less than 1% of patients suffering from rheumatoidarthritis (RA), a condition known as Felty syndrome(FS) can develop.1,2 FS, first described by the American
physician Augustus Roi Felty in 1924, is characterized by
the triad of RA, (unexplained) neutropenia, and
splenomegaly, and is more common in people aged 50
years and over. In spite of the clear association with RA,
the common underlying cause of all three characteristic
symptoms remains largely elusive. It is known that FS
shows an overlap with a rare type of T-cell leukemia,
called T-cell large granular lymphocyte (T-LGL) leukemia,
which also typically presents in elderly individuals with a
median age of 60 years. In fact, T-LGL leukemia patients
can show all the features that FS patients have, albeit at
varying frequencies, thus making the differential diagno-
sis between LGL leukemia and FS problematic at times.3
An additional complication to that of the overlapping
clinical features is the fact that both conditions share the
presence of LGL cells.  
Based on the overlapping features, Savola and col-
leagues explored a potential common pathogenic mecha-
nism between FS and LGL leukemia. In this issue of
Haematologica they report on a cohort of 14 FS patients,
which were evaluated by next-generation sequencing
(NGS) technology for the occurrence of somatic muta-
tions in the STAT3 and STAT5B genes.4 Both of these
genes have been notably implicated in a subset of the
CD8+ TCRαβ+ T-cell type of LGL leukemia, and the
occurrence of STAT3 mutations in LGL leukemia is
strongly associated with RA and neutropenia.5-7 Indeed, in
>40% of FS cases somatic STAT3 hotspot mutations were
found, which is at a rate comparable to LGL leukemia
cases. The fact  that the STAT3 variant allele frequencies
were lower in FS can be explained by the smaller T-cell
clone sizes in FS patients. Nevertheless, LGL cell propor-
tions were increased in FS patients, and in two cases the
LGL cell numbers additionally fulfilled the criteria for
LGL lymphocytosis. Taken together, these observations
firmly support the idea that FS and LGL leukemia are part
of a disease spectrum with a common pathogenesis, in
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Figure 1. Overlap between LGL leukemia / proliferation and immune dysregu-
lation diseases and conditions that show an increase of LGL cells and/or the
presence of STAT3 mutated cells. AA: aplastic anemia; CD: celiac disease; FS:
Felty syndrome; MDS: myelodysplastic syndrome; PNH: paroxysmal nocturnal
hemoglobinuria; PRCA: pure red cell aplasia; LGL: large granular lymphocyte.
which LGL leukemia ranges from poly/oligoclonal to
monoclonal.8 The concept of a disease continuum is fur-
ther strengthened by the observation that IL-15RA and
CXCL10 levels are also increased in both conditions.
Hitherto, the occurrence of LGL cells and clones were
associated with bone marrow failure syndromes such as
aplastic anemia (AA) and (hypoplastic) myelodysplastic
syndrome (MDS), both of which are believed to reflect an
autoimmune pathogenesis.9,10 However, in conditions
such as pure red cell aplasia (PRCA), characterized by the
killing of red cell precursors, and paroxysmal nocturnal
hemoglobinuria (PNH), characterized by the comple-
ment-mediated destruction of red blood cells, LGL prolif-
erations have also been reported.11,12 It is of interest that in
many of these conditions STAT3 mutations have been
documented. The current description of high LGL counts
and STAT3 mutations in FS thus extends the spectrum of
immune dysregulation disease conditions in which LGL
cells are prominently associated (Figure 1). Notably, in
their series, Savola et al. found four FS cases that also
showed celiac disease (CD),4 which confirms earlier sug-
gestions of links between LGL cells, STAT3 mutations,
and CD.13,14
The presumed common pathogenesis of LGL leukemia
and immune dysregulations such as FS, CD, and bone
marrow failure and related conditions (AA, hypoplastic
MDS, PNH) would pave the way for more sophisticated
treatment strategies than the current general immune
suppressive modalities which are frequently applied.15
Such targeted strategies would have to exploit common
molecular aberrations, one of the most promising
approaches being STAT3 inhibition in JAK/STAT hyper-
active LGL cells. This is of special interest as constitutive
STAT activation is observed in almost all LGL prolifera-
tions regardless of the presence of mutations in the STAT3
gene.16 In addition, specific inhibition of JAK family kinas-
es with the AG-490 tyrosine kinase inhibitor has been
demonstrated to induce apoptosis of LGL leukemia cells
in vitro and antisense oligonucleotide therapy to inhibit
STAT3 activation, which has been shown to restore FAS
sensitivity in LGL leukemia cells.17 However, further
investigation into other common molecular aberrations
might reveal distinct molecular mechanisms or pathways
in subgroups of these diseases, which could be targeted
by yet different molecule-centered treatment strategies.
This would require deep sequencing approaches in larger
cohorts, and might have to go beyond genomics by
studying the transcriptome, the epigenome, and perhaps
also small non-coding RNAs.
In all the associations between LGL leukemia / prolifer-
ations and immune dysregulations, however, one central
question remains to be addressed more definitely; “the
chicken or the egg” question. In other words, in scientific
parlance, are LGL cells truly causing the immune dysreg-
ulation, or is their presence more likely to be an epiphe-
nomenon as a consequence of chronic (auto)antigen stim-
ulation in these conditions? Based on existing literature, it
is tempting to speculate that LGL cells have an authentic
causative role, nevertheless, before definite conclusions
can be drawn further research is required. This should
undoubtedly include studies that aim to eradicate the
LGL clones in patients through targeted treatment, and
which could categorically disclose the presumed
causative role of LGL cells. 
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